BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28440032)

  • 1. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B.
    Kihlberg K; Strandberg K; Rosén S; Ljung R; Astermark J
    Haemophilia; 2017 Jul; 23(4):620-627. PubMed ID: 28440032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-stage vs. chromogenic assays in haemophilia A.
    Potgieter JJ; Damgaard M; Hillarp A
    Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay discrepancy in mild haemophilia A.
    Armstrong E; Hillarp A
    Eur J Haematol Suppl; 2014 Aug; 76():48-50. PubMed ID: 24957107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
    Marlar RA; Strandberg K; Shima M; Adcock DM
    Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Little discrepancy between one-stage and chromogenic factor VIII (FVIII)/IX assays in a large international cohort of persons with nonsevere hemophilia A and B.
    Zwagemaker AF; Kloosterman FR; Gouw SC; Boyce S; Brons P; Cnossen MH; Collins PW; Eikenboom J; Hay C; Hengeveld RCC; Jackson S; Klopper-Tol CAM; Kruip MJHA; Gorkom BL; Male C; Nieuwenhuizen L; Shapiro S; Fijnvandraat K; Coppens M;
    J Thromb Haemost; 2023 Apr; 21(4):850-861. PubMed ID: 36696222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V; Jouppila A; Lassila R
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of chromogenic assays in haemophilia A and B diagnosis.
    Bowyer AE; Duncan EM; Antovic JP
    Haemophilia; 2018 Jul; 24(4):578-583. PubMed ID: 29808946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Haemophilia].
    Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
    Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.
    Cid AR; Calabuig M; Cortina V; Casaña P; Haya S; Moret A; Cabrera N; Aznar JA
    Haemophilia; 2008 Sep; 14(5):1049-54. PubMed ID: 18540892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
    Schütte LM; Hodes LS; van Moort I; Stoof SCM; Leebeek FWG; Cnossen MH; de Maat MPM; Kruip MJHA
    Haemophilia; 2020 Sep; 26(5):916-922. PubMed ID: 32713129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
    Adcock DM; Strandberg K; Shima M; Marlar RA
    Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV; Hogwood J; Gray E
    Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
    Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
    Pezeshkpoor B; Gazorpak M; Berkemeier AC; Singer H; Pavlova A; Biswas A; Oldenburg J
    Ann Hematol; 2019 Aug; 98(8):1855-1865. PubMed ID: 30997536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre.
    Poulsen AL; Pedersen LH; Hvas AM; Poulsen LH; Thykjaer H; Ingerslev J
    Haemophilia; 2009 Jan; 15(1):285-9. PubMed ID: 19149854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
    Kitchen S; Signer-Romero K; Key NS
    Haemophilia; 2015 Jul; 21(4):550-7. PubMed ID: 25688866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.